人卵巢癌细胞OVCA433

细胞名称

人卵巢癌细胞OVCA433

货物编码

BFN60808639

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研      2类

培养体系

DMEM高糖+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人卵巢癌细胞OVCA433取自女性供体，贴壁培养。

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Doubling time: 102.24 hours (https://www.synapse.org/#!Synapse:syn2347014).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Exosome proteome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突变

/

HLA信息

/

STR信息

Amelogenin        X

CSF1PO        12,13

D2S1338        19,20

D3S1358        15,16

D5S818        11,12

D7S820        11,12

D8S1179        14,15

D13S317        7,12

D16S539        12

D18S51        14

D19S433        13

D21S11        30

FGA        24

Penta D        13,14

Penta E        7,12

TH01        9

TPOX        9,11

vWA        16,18

参考文献

PubMed=24434149; DOI=10.1016/j.bbrc.2013.12.070

Sinha A., Ignatchenko V., Ignatchenko A., Mejia-Guerrero S., Kislinger T.

In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.

Biochem. Biophys. Res. Commun. 445:694-701(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27561551; DOI=10.1038/ncomms12645

Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Nat. Commun. 7:12645-12645(2016)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028

Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A., Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R., Ailles L., Mes-Massons A.-M., Rottapel R.

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Cell Rep. 18:2343-2358(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)